Nanobiotix Investor Relations Material

Nanobiotix S.A. is a biotechnology company that focuses on developing nanomedicine products for cancer treatment. The company's proprietary technology, NanoXray, involves nanoparticles that enhance the effects of radiotherapy by increasing the absorption of X-rays within cancer cells. This approach is designed to improve the precision and effectiveness of radiotherapy, potentially reducing side effects and improving patient outcomes. Nanobiotix's products are primarily in the clinical stages of development, and the company continues to advance its pipeline for various cancer types. The company is headquartered in Paris, France, and its shares are listed on the Euronext Paris.